Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 2/20 | 0.32 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.30 |
| ▸ | DGKA | P23743 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9146865 | 0.91 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL28905521 | 0.78 | USP2 (0.30) | — | |
| SCHEMBL16146979 | 0.72 | NAAA (0.33) | SMN1; SMN2NAAA | |
| SCHEMBL29199165 | 0.72 | TSHR (0.49) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL15392387 | 0.71 | — | — | |
| Sebacic Acid SCHEMBL27841725 | 0.70 | CYP1A2 (0.42) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL28288158 | 0.69 | NAAA (0.38) | SMN1; SMN2ALDH1A1L3MBTL1NAAADGKA | |
| SCHEMBL194968 | 0.69 | NAAA (0.38) | SMN1; SMN2ALDH1A1L3MBTL1NAAADGKA | |
| SCHEMBL27703376 | 0.69 | NAAA (0.38) | SMN1; SMN2ALDH1A1L3MBTL1NAAADGKA | |
| SCHEMBL15392711 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1070102-B1 | ANTIFOULANT COMPOSITIONS AND METHODS OF TREATING WOOD | BURLINGTON BIO MED & SCIENT (US) | 2004-06-16 | — | — | EP | claimed |
| US-6207290-B1 | QUATERNARY AMMONIUM SALT AND ARSENIC COMPOUNDS AND ULTRAVIOLET RADIATION ABSORBERS | BURLINGTON BIO-MEDICAL & SCIENTIFIC CORP. | 2001-03-27 | — | — | US | claimed |
| EP-1070102-A1 | ANTIFOULANT COMPOSITIONS AND METHODS OF TREATING WOOD | Burlington Bio-Medical & Scientific Corp. (US) | 2001-01-24 | — | — | EP | claimed |
| WO-1999051694-A1 | ANTIFOULANT COMPOSITIONS AND METHODS OF TREATING WOOD | BURLINGTON BIO-MEDICAL & SCIENTIFIC CORP. (US) | 1999-10-14 | — | — | WO | claimed |
| JP-62007752-A | — | — | None | — | — | JP | disclosed |
| JP-59019195-A | — | — | None | — | — | JP | disclosed |
| US-9018319-B2 | Radical-curable hot-melt urethane resin composition and optical molded body | DIC CORPORATION (JP) | 2015-04-28 | — | — | US | disclosed |
| US-20140303330-A1 | RADICAL-CURABLE HOT-MELT URETHANE RESIN COMPOSITION AND OPTICAL MOLDED BODY | DIC CORPORATION (JP) | 2014-10-09 | — | — | US | disclosed |
| US-7582783-B2 | Analgesics, anaesthetics, antifoulants, aversants, irritants, incapacitants and compositions containing the same | WHITE FLOWER ASSOCIATES LLP (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070225515-A1 | Analgesics, anaesthetics, antifoulants, aversants, irritants, incapacitants and compositions containing the same | WHITE FLOWER ASSOCIATES LLP (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1070102-B1 | ANTIFOULANT COMPOSITIONS AND METHODS OF TREATING WOOD | BURLINGTON BIO MED & SCIENT (US) | 2004-06-16 | — | — | EP | disclosed |
| US-6207290-B1 | QUATERNARY AMMONIUM SALT AND ARSENIC COMPOUNDS AND ULTRAVIOLET RADIATION ABSORBERS | BURLINGTON BIO-MEDICAL & SCIENTIFIC CORP. | 2001-03-27 | — | — | US | disclosed |
| EP-1070102-A1 | ANTIFOULANT COMPOSITIONS AND METHODS OF TREATING WOOD | Burlington Bio-Medical & Scientific Corp. (US) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999051694-A1 | ANTIFOULANT COMPOSITIONS AND METHODS OF TREATING WOOD | BURLINGTON BIO-MEDICAL & SCIENTIFIC CORP. (US) | 1999-10-14 | — | — | WO | disclosed |
| JP-S627752-A | RESIN COMPOSITION | DENKI KAGAKU KOGYO KK | 1987-01-14 | — | — | JP | disclosed |
| JP-S5919195-A | HEAT SENSITIVE RECORDING MATERIAL | SHIN NISSO KAKO CO LTD | 1984-01-31 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225515-A1 | Analgesics, anaesthetics, antifoulants, aversants, irritants, incapacitants and compositions containing the same | ACHE, BCHE, TRPA1 | SMN1; SMN2 671/4885ALDH1A1 1031/4885L3MBTL1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.